NCT01384994 - Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2014

Conditions

Colorectal CancerKRAS WildtypeAfter Resection of Liver Metastases

Interventions

DRUG

Folic Acid

400 mg/m2, 2h infusion, d1, q2w

DRUG

5-FU

400 mg/m2 bolus iv, d1, q2w

DRUG

5-FU

2400 mg/m2 46-h infusion, d1-2, q2w

DRUG

Oxaliplatin

85 mg/m2 d1, q2w

DRUG

Panitumumab

6 mg/kg BW every 2 weeks

DRUG

Panitumumab

Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks

DRUG

Folic Acid

400 mg/m2, 2-h infusion, d1, q2w

DRUG

5-FU

400 mg/m2 bolus iv, d1, q2w

DRUG

5-FU

2400 mg/m2 46-h infusion, d1-2, q2w

DRUG

Oxaliplatin

85 mg/m2 d1, q2w

Trial Locations (1)

RECRUITING

Ludwig-Maximilians - University of Munich, Munich